On August 11, Hims & Hers Health Inc. declined 7.11% overnight, trading at $29.51/share. The selloff was triggered by the company's Q2 earnings report revealing a per-share loss of $0.37, drastically worse than the market consensus estimate of a $0.03-$0.05 loss, and a sharp reversal from the $0.17 per-share profit in the year-ago quarter.

Despite revenue of $753 million beating expectations with 38% year-over-year growth and total subscribers reaching approximately 2.89 million, the profit deterioration alarmed investors. Gross margin contracted significantly from 76% to 64%, driven by the company's aggressive push into branded GLP-1 weight-loss products and international market expansion. The CFO confirmed these newer business lines carry structurally lower margins than core operations and will keep profitability below historical levels going forward.

Management raised full-year revenue guidance to $3.1-3.3 billion from the prior $2.8-3.0 billion range and expressed confidence in its 2030 target of at least $6.5 billion in revenue. However, the magnitude of the earnings miss overshadowed these positive signals, pressuring shares in overnight trading.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)